SCHEMBL29619165

SCHEMBL29619165

Cc1noc(C)c1-c1cc(NC(=O)C2CC2)ccc1OCCN1C[C@@H]2C[C@H]1CO2

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.41
HTR2A P28223 2/20 0.40
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE5A O76074 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
GABRA5 P31644 1/20 0.37
WNT3A P56704 1/20 0.37
CREBBP Q92793 1/20 0.36
HTR2C P28335 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
WNT1 P04628 2/20 0.36
GSK3B P49841 2/20 0.36
DYRK1A Q13627 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31677761 0.90 HTR2A (0.41) FLT3HTR2APDE5AJAK2JAK1
SCHEMBL29619028 0.88 FLT3 (0.41) FLT3HTR2AWNT3ACREBBPHTR2C
SCHEMBL29619114 0.88 WNT3A (0.44) FLT3HTR2AMAPTLMNAWNT3A
SCHEMBL29619067 0.87 HTR2A (0.40) FLT3HTR2AWNT3ACREBBPHTR2C
SCHEMBL29619066 0.87 HTR2A (0.40) FLT3HTR2AWNT3ACREBBPHTR2C
SCHEMBL29619036 0.84 HTR2A (0.42) HTR2AMAPTLMNASMN1; SMN2PDE5A
SCHEMBL29619038 0.84 HTR2A (0.42) HTR2AMAPTLMNASMN1; SMN2PDE5A
SCHEMBL29619000 0.83 MAPT (0.45) HTR2AMAPTLMNASMN1; SMN2PDE5A
SCHEMBL29619001 0.82 ESR1 (0.35) FLT3PDE5A
SCHEMBL29619005 0.82 ESR1 (0.35) FLT3PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed
EP-4236942-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2023-09-06 EP disclosed
WO-2022093850-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO HTR2A, HTR5A, HTR1A FLT3 4847/4885HTR2A 1/4885MAPT 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.